Menu
Back to Journals » Therapeutics and Clinical Risk Management » Volume 9
Current and emerging management options for patients with Morquio A syndrome
Authors Algahim M, Almassi GH
Received 14 November 2012
Accepted for publication 4 January 2013
Published 11 February 2013 Volume 2013:9 Pages 45—53
DOI https://doi.org/10.2147/TCRM.S24771
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Mohamed F Algahim, G Hossein Almassi
Division of Cardiothoracic Surgery, Medical College of Wisconsin, Milwaukee, WI, USA
Abstract: Morquio A syndrome is a lysosomal storage disease associated with mucopolysaccharidosis. It is caused by a deficiency of the lysosomal enzyme, N-acetylgalactosamine-6-sulfate sulfatase, which leads to accumulation of keratan sulfate and condroitin-6 sulfate in multiple organs. Patients present with multisystemic complications involving the musculoskeletal, respiratory, cardiovascular, and digestive systems. Presently, there is no definitive cure, and current management options are palliative. Enzyme replacement therapy and hematopoietic stem cell therapy have been proven effective in certain lysosomal storage diseases, and current investigations are underway to evaluate the effectiveness of these therapies and others for the treatment of Morquio A syndrome. This review discusses the current and emerging treatment options for Morquio A syndrome, citing examples of the treatment of other mucopolysaccharidoses.
Keywords: lysosomal, storage disease, mucopolysaccharidosis
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.